Plant-Derived Compounds for Bone Health and Osteoporosis

Dr. Haruto Takashi Fujimoto [1*], Dr. Aiko Miyazaki Nakamura [2]
[1] Department of Pharmaceutical Nanoscience, University of Tokyo, Japan
[2] Institute of Advanced Drug Delivery Systems, Kyoto University, Japan

* Corresponding Author: **Dr. Haruto Takashi Fujimoto**

Article Info

ISSN (online): 3107-393X
Volume: 02
Issue: 03
May-June 2025
Received: 19-03-2025
Accepted: 22-04-2025
Published: 18-05-2025
Page No: 40-47

Abstract
Osteoporosis is a progressive systemic skeletal disorder characterized by reduced bone mineral density and deterioration of bone microarchitecture, representing one of the foremost public health challenges of the twenty-first century. With an estimated 200 million individuals affected worldwide and a substantial burden of fragility fractures associated with significant morbidity, mortality, and healthcare expenditure, the need for effective, safe, and sustainable therapeutic strategies remains acute. Current pharmacological options, including bisphosphonates, selective estrogen receptor modulators, and parathyroid hormone analogues, are associated with adverse effects such as osteonecrosis of the jaw, atypical femoral fractures, cardiovascular risks, and poor long-term tolerability, thereby limiting their widespread and prolonged use. This review comprehensively examines the evidence pertaining to plant-derived compounds, including flavonoids, phytoestrogens, polyphenols, and terpenoids, as adjunctive or alternative agents in the prevention and management of osteoporosis. Mechanistically, these phytochemicals exert their osteogenic effects through stimulation of osteoblast proliferation and differentiation, inhibition of osteoclastogenesis via modulation of the RANKL/RANK/OPG axis, reduction of oxidative stress, and hormonal modulation through estrogen receptor pathways. Preclinical evidence from *in vitro* and animal studies demonstrates considerable promise, while clinical trials provide preliminary validation of efficacy and safety. Despite encouraging findings, significant challenges remain in the areas of bioavailability, standardization of plant extracts, and translation from bench to bedside. This review synthesizes current knowledge, critically evaluates translational challenges, and highlights future directions for the integration of plant-derived compounds into mainstream osteoporosis therapeutics.

Keywords: Plant-derived compounds, Osteoporosis, Bone health, Phytochemicals, Bone metabolism, Translational research

1. Introduction

Osteoporosis is defined by the World Health Organization as a bone mineral density (BMD) T-score of -2.5 or below at the femoral neck or lumbar spine, reflecting a state of skeletal fragility that predisposes affected individuals to fractures following minimal trauma [1]. It is estimated that one in three women and one in five men over the age of fifty will sustain an osteoporotic fracture during their lifetime, with hip fractures alone accounting for approximately 1.6 million incidents globally per annum [2]. The socioeconomic impact of osteoporosis is enormous, with projected costs exceeding USD 25 billion annually in the United States alone by 2025 [3]. Beyond osteoporosis, conditions such as osteopenia, glucocorticoid-induced bone loss, and secondary osteoporosis associated with malignancy, inflammatory diseases, and hormonal deficiencies further underscore the magnitude of bone health as a clinical priority [4].

The pathophysiology of osteoporosis involves a fundamental imbalance between bone formation and bone resorption, mediated by complex interactions among osteoblasts, osteoclasts, and osteocytes within the bone remodeling unit [5]. Hormonal factors,

particularly the decline in estrogen following menopause, play a pivotal role in accelerating bone resorption and suppressing bone formation, thereby driving the postmenopausal osteoporosis that accounts for the majority of cases in women [6]. Conventional pharmacotherapy, while effective in reducing fracture risk, is characterized by significant limitations. Bisphosphonates, the most widely prescribed agents, are associated with gastrointestinal intolerance, osteonecrosis of the jaw, and the paradoxical risk of atypical femoral fractures with prolonged use [7]. Anabolic agents such as teriparatide are expensive and restricted in their duration of use, while newer biological agents such as denosumab and romosozumab entail elevated cardiovascular and immunological risks [8]. These considerations have stimulated considerable scientific and clinical interest in plant-derived compounds as potentially safer and more sustainable therapeutic alternatives.

The ethnopharmacological record is replete with examples of plants historically employed in the management of musculoskeletal disorders, and contemporary phytochemical research has yielded substantial evidence for the osteogenic and anti-resorptive activities of numerous plant-derived molecules [9]. Flavonoids, polyphenols, phytoestrogens, and terpenoids have all been identified as modulators of bone metabolism through a variety of molecular mechanisms [10]. This review aims to provide a comprehensive, critically analyzed account of the current state of knowledge regarding plant-derived compounds for bone health, encompassing the molecular mechanisms underlying their activity, the preclinical and clinical evidence supporting their use, and the translational challenges that must be addressed to realize their therapeutic potential.

2. Physiology of Bone Metabolism and Remodeling

Bone is a highly dynamic tissue that undergoes continuous renewal through a tightly regulated process known as bone remodeling, wherein old or damaged bone is removed by osteoclasts and subsequently replaced by new bone deposited by osteoblasts [11]. This cycle is orchestrated through the coordinated activity of multiple cell types within the basic multicellular unit (BMU), including osteoclasts of hematopoietic origin, osteoblasts derived from mesenchymal stem cells, and the mechanosensory osteocytes embedded within the mineralized matrix [12]. The remodeling cycle progresses through sequential phases of activation, resorption, reversal, formation, and quiescence, each governed by a distinct set of molecular signals [13].

Central to the regulation of bone remodeling is the RANKL (receptor activator of nuclear factor kappa-B ligand) / RANK / OPG (osteoprotegerin) axis, wherein RANKL expressed by osteoblasts and stromal cells binds to RANK on osteoclast precursors to promote osteoclastogenesis and bone resorption, while OPG secreted by osteoblasts acts as a decoy receptor to inhibit RANKL activity [14]. The Wnt/beta-catenin signaling pathway is equally critical for osteoblast differentiation and bone formation, with sclerostin produced by osteocytes serving as a negative regulator of this pathway [15]. Additional mediators including transforming growth factor beta (TGF-beta), bone morphogenetic proteins (BMPs), insulin-like growth factors (IGFs), and various pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor alpha (TNF-alpha) contribute to the complex regulatory landscape of bone metabolism [16].

Hormonal regulation of bone remodeling is mediated principally by estrogen, parathyroid hormone (PTH), calcitonin, vitamin D, and glucocorticoids. Estrogen exerts a predominantly anti-resorptive influence through suppression of osteoclast activity and promotion of osteoclast apoptosis, while also supporting osteoblast survival [17]. The precipitous decline in circulating estrogen following menopause disrupts this equilibrium, leading to accelerated bone turnover with net resorption and consequent reduction in BMD [18]. Understanding these physiological mechanisms provides an essential framework for elucidating the pharmacological actions of plant-derived compounds that target analogous pathways to restore or maintain bone homeostasis.

3. Classification and Sources of Plant-Derived Compounds

Plant-derived compounds relevant to bone health encompass a chemically diverse array of secondary metabolites, broadly classified into flavonoids, phytoestrogens, polyphenols, and terpenoids, each with distinct structural characteristics, sources, and pharmacological profiles [19].

Flavonoids constitute the largest class of plant polyphenols, characterized by a C6-C3-C6 diphenylpropane carbon skeleton, and include subclasses such as flavones, flavonols, flavanones, isoflavones, anthocyanins, and catechins [20]. Rich dietary sources include citrus fruits, berries, onions, green tea, red wine, and numerous medicinal herbs. Quercetin, kaempferol, naringenin, and rutin are among the most extensively studied flavonoids in the context of bone metabolism. Phytoestrogens represent a structurally and functionally distinct category, encompassing isoflavones (genistein, daidzein, formononetin), lignans, coumestans, and stilbenes, derived primarily from soy products, flaxseed, red clover, and kudzu root [21]. Their structural similarity to 17-beta-estradiol enables selective binding to estrogen receptors, making them particularly relevant to postmenopausal bone loss.

Polyphenols beyond the flavonoid subclass include resveratrol, curcumin, ellagic acid, and gallic acid, derived from grapes, turmeric, pomegranate, and various berries respectively [22]. These compounds exhibit pronounced antioxidant and anti-inflammatory properties in addition to direct effects on bone cell function. Terpenoids, including monoterpenes, diterpenes, and triterpenes such as ursolic acid, oleanolic acid, and betulinic acid, are widely distributed across the plant kingdom and have been identified as modulators of osteoblast and osteoclast activity [23]. Additional categories of pharmacological relevance include alkaloids, saponins, and essential fatty acids, all of which have been associated with skeletal benefits in preclinical investigations. An overview of representative compounds, their botanical sources, and primary mechanisms of action is presented in Table 1.

Table 1: Plant-Derived Compounds, Botanical Sources, and Mechanisms of Action in Bone Health

Compound	Class	Botanical Source	Primary Mechanism	Key Target/Pathway
Genistein	Isoflavone	Soybean (Glycine max)	Estrogen receptor agonism; osteoblast stimulation; osteoclast inhibition	ERalpha/ERbeta; RANKL/OPG
Quercetin	Flavonol	Onion, apple, green tea	Anti-oxidative; promotes osteoblast differentiation; inhibits osteoclastogenesis	Nrf2; Wnt/beta-catenin
Resveratrol	Stilbene polyphenol	Red grapes, Polygonum cuspidatum	Sirtuin activation; anti-inflammatory; osteoblast differentiation	SIRT1; NF-kappaB; Runx2
Curcumin	Curcuminoid polyphenol	Turmeric (Curcuma longa)	NF-kappaB inhibition; RANKL suppression; antioxidant	NF-kappaB; RANKL; BMP-2
Formononetin	Isoflavone	Red clover (Trifolium pratense)	Estrogen receptor modulation; promotes bone formation	ERbeta; OPG/RANKL ratio
Kaempferol	Flavonol	Broccoli, kale, tea	Osteoblast proliferation; inhibits osteoclast differentiation	BMP-2; Runx2; RANKL
Ursolic acid	Pentacyclic triterpene	Apple peel, rosemary, thyme	Osteogenic gene expression; anti-inflammatory	Wnt; IGF-1; NF-kappaB
Naringenin	Flavanone	Citrus fruits	Promotes bone mineral density; estrogenic activity	ERalpha; Runx2; collagen
Berberine	Isoquinoline alkaloid	Berberis spp., goldenseal	Osteoblast differentiation; RANKL inhibition	AMPK; BMP-2; OPG
Puerarin	Isoflavone glycoside	Kudzu root (Pueraria lobata)	Phytoestrogenic; stimulates osteoblasts	ERbeta; BMP-2; Runx2

4. Mechanisms of Action in Bone Health

4.1. Stimulation of Bone Formation

The stimulation of osteoblastogenesis and bone formation represents one of the primary mechanisms by which plant-derived compounds contribute to skeletal health. Flavonoids such as quercetin and kaempferol have been demonstrated to enhance the differentiation of mesenchymal stem cells toward the osteogenic lineage through upregulation of key transcription factors including Runx2 (runt-related transcription factor 2) and osterix, which are indispensable for osteoblast maturation and function [24]. Genistein, the principal soy isoflavone, activates estrogen receptor beta (ERbeta) to promote osteoblast proliferation, increase alkaline phosphatase activity, and enhance the deposition of mineralized matrix *in vitro* [25]. Resveratrol activates SIRT1 deacetylase, which in turn potentiates beta-catenin nuclear translocation, thereby activating the canonical Wnt signaling pathway and promoting bone formation [26]. The BMP-2 (bone morphogenetic protein 2) pathway, a major driver of osteogenic differentiation, is upregulated by curcumin and puerarin, further illustrating the diversity of anabolic mechanisms engaged by phytochemicals.

4.2. Inhibition of Bone Resorption

Anti-resorptive activity constitutes an equally important dimension of the osteogenic pharmacology of plant-derived compounds. The RANKL/RANK/OPG signaling axis is a central target in this regard. Curcumin, formononetin, and berberine have all been shown to suppress RANKL expression and/or enhance OPG production in osteoblasts, thereby shifting the OPG-to-RANKL ratio in favor of reduced osteoclastogenesis [27]. Quercetin inhibits the differentiation of osteoclast precursors from hematopoietic progenitors by blocking NF-kappaB nuclear translocation, a key downstream event in RANK signaling [28]. Genistein has been demonstrated to induce apoptosis of mature osteoclasts, reducing the number of bone-resorbing cells independent of effects on their differentiation [29]. The mitogen-activated protein kinase (MAPK) pathways, including ERK and JNK, which mediate osteoclast survival and activity, are also suppressed by several polyphenols, providing additional mechanistic substrates for their anti-resorptive effects.

4.3. Antioxidant Activity and Oxidative Stress Modulation

Oxidative stress plays an increasingly recognized role in the pathogenesis of osteoporosis, as reactive oxygen species (ROS) promote osteoclast differentiation while suppressing osteoblast survival and function [30]. Plant-derived compounds, by virtue of their capacity to scavenge free radicals, chelate metal ions, and activate endogenous antioxidant defense systems, confer indirect skeletal protection through reduction of oxidative damage. Resveratrol and quercetin activate the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor, which drives the expression of antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase [31]. Curcumin similarly upregulates heme oxygenase-1 (HO-1) and reduces lipid peroxidation in osteoblastic cells, thereby promoting their survival and synthetic activity under conditions of oxidative challenge [32]. These antioxidant mechanisms are particularly relevant in the context of aging and glucocorticoid-induced bone loss, where oxidative stress is markedly elevated.

4.4. Hormonal Modulation

The phytoestrogenic isoflavones occupy a unique niche in osteoporosis pharmacology by virtue of their ability to interact directly with estrogen receptors. Genistein and daidzein exhibit preferential affinity for ERbeta over ERalpha, engaging tissue-selective estrogenic effects that include maintenance of bone density while potentially minimizing risks associated with estrogen-sensitive malignancies [33]. The metabolic conversion of daidzein to equol by intestinal microbiota significantly enhances its estrogenic potency, introducing an important source of inter-individual variability in response [34].

Formononetin, derived from red clover, and puerarin from kudzu root similarly engage ERbeta to stimulate osteoblastic activity and suppress osteoclastogenesis in postmenopausal animal models. Certain terpenoids, while lacking direct estrogenic activity, modulate the hypothalamic-pituitary-gonadal axis or interact with androgen receptors, providing ancillary hormonal support for skeletal maintenance. These phytoestrogenic mechanisms are of particular relevance to the management of postmenopausal osteoporosis.

5. Preclinical and Translational Research

Preclinical investigation of plant-derived compounds for bone health has been conducted across a spectrum of experimental models, ranging from cell culture systems to ovariectomized rodent models that recapitulate postmenopausal osteoporosis [35]. *in vitro* studies using osteoblastic cell lines such as MC3T3-E1, MG-63, and primary human osteoblasts, as well as osteoclast precursor cultures derived from RAW 264.7 macrophages and bone marrow mononuclear cells, have provided mechanistic insights into the cellular and molecular effects of phytochemicals. These systems, however, are inherently limited in their capacity to replicate the complex three-dimensional architecture and dynamic cellular interactions of living bone tissue.

Animal models, particularly the ovariectomized (OVX) rat and mouse, have been extensively employed to evaluate the *in vivo* efficacy of plant-derived compounds. Studies in OVX rodents have demonstrated that isoflavones, most notably genistein, significantly attenuate bone loss as measured by dual-energy X-ray absorptiometry (DEXA), microcomputed tomography (micro-CT), and histomorphometric analysis [36]. Resveratrol supplementation has similarly been shown to improve trabecular microarchitecture and increase serum markers of bone formation such as osteocalcin and procollagen type I N-terminal propeptide (P1NP) in OVX models. Additional models employed include the senescence-accelerated mouse (SAM), glucocorticoid-treated animals, and sciatic neurectomy models of disuse osteopenia.

A critical concern in the translational application of these findings relates to pharmacokinetics. Many plant-derived compounds suffer from poor oral bioavailability attributable to low aqueous solubility, rapid first-pass metabolism, and extensive conjugation and glucuronidation in the gut and liver. Curcumin, despite its impressive *in vitro* profile, exhibits less than one percent oral bioavailability in native form, substantially limiting its *in vivo* activity [37]. Similarly, resveratrol undergoes rapid hepatic metabolism to sulfate and glucuronide conjugates, reducing plasma concentrations of the active aglycone. Genistein has comparatively favorable pharmacokinetics, achieving peak plasma concentrations in the low micromolar range following dietary consumption of soy, which are sufficient to engage estrogen receptor-mediated effects. Addressing these pharmacokinetic barriers through advanced formulation strategies, discussed in Section 7, is therefore a prerequisite for the successful translation of preclinical findings.

6. Clinical Evidence: Efficacy, Safety, and Limitations

The clinical evidence base for plant-derived compounds in osteoporosis management, while growing, remains considerably less mature than the preclinical literature. Randomized controlled trials (RCTs) have been conducted primarily with isoflavones, evaluating their effects on BMD, bone turnover markers, and fracture incidence in postmenopausal women [38]. A meta-analysis of fourteen RCTs by Taku and colleagues demonstrated that soy isoflavone supplementation produced a statistically significant improvement in lumbar spine BMD and reductions in urinary deoxypyridinoline, a marker of bone resorption, compared with placebo [39]. The magnitude of effect, while modest in absolute terms, is clinically meaningful in the context of long-term prevention strategies. A summary of clinical studies is presented in Table 2.

Genistein aglycone has been the subject of several well-designed trials. The GENOSS study, conducted in Italian postmenopausal women, reported that daily supplementation with 54 mg of genistein over two years produced significant gains in femoral neck and lumbar spine BMD, with a favorable safety profile and no increase in breast or endometrial tissue stimulation [40]. Resveratrol has been evaluated in smaller clinical studies, with the RESHAW trial demonstrating improvements in spinal BMD and bone formation markers in postmenopausal women supplemented with 75 mg twice daily [41]. Curcumin-based formulations have shown promise in reducing bone resorption markers in clinical settings, though robust BMD data from adequately powered trials remain limited.

Limitations inherent in the existing clinical literature are substantial. Heterogeneity in extract composition, dosing regimens, treatment durations, patient populations, and outcome measures complicates meta-analytical synthesis and limits the generalizability of individual trial findings. The bioavailability challenges discussed above mean that the dose required for clinical efficacy may differ substantially from those tested in trials, and standardization of phytochemical content in commercial preparations is inconsistent. Adverse effects are generally mild, including gastrointestinal symptoms and, for high-dose isoflavones, concerns regarding potential stimulation of hormone-sensitive tissues in women with relevant risk factors. Fracture endpoint data remain sparse, as existing trials are insufficiently powered and of inadequate duration to detect differences in clinical fracture rates. Despite these limitations, the aggregate evidence is encouraging and justifies continued investment in high-quality clinical research.

Table 2: Summary of Clinical Evidence for Selected Plant-Based Therapies in Osteoporosis

Compound	Population	Dose/Duration	Primary Endpoint	Key Finding	Safety
Genistein (GENOSS)	Postmenopausal women (n=389)	54 mg/day, 2 years	Lumbar spine & femoral neck BMD	Significant BMD gain vs placebo	No endometrial stimulation; well tolerated
Soy isoflavone mixture	Postmenopausal women (meta-analysis, 14 RCTs)	Variable (40-120 mg/day)	Lumbar BMD; urinary DPD	Modest BMD increase; reduced bone resorption	Generally mild GI events
Resveratrol (RESHAW)	Postmenopausal women (n=66)	75 mg BID, 12 months	Lumbar spine BMD	Improved BMD and bone formation markers	Well tolerated; mild GI symptoms
Formononetin (red clover)	Postmenopausal women (n=205)	40 mg/day, 12 months	Proximal femur BMD	Reduced bone loss at proximal femur	No serious adverse events
Curcumin formulation	Osteopenic women (n=57)	1000 mg/day, 6 months	Bone turnover markers (CTX, P1NP)	Reduced CTX; trend toward improved P1NP	Mild GI effects; generally safe

7. Formulation Strategies and Advanced Delivery Systems

Given the recognized pharmacokinetic deficiencies of many plant-derived bioactives, considerable research effort has been directed toward the development of advanced delivery platforms capable of enhancing solubility, stability, absorption, and targeted delivery to bone tissue [42]. Nanoparticulate systems represent the most extensively investigated approach, encompassing polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, and liposomal formulations. Curcumin encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles exhibits dramatically enhanced oral bioavailability and sustained plasma levels compared with unformulated curcumin, and has demonstrated superior *in vivo* efficacy in osteoporotic animal models [43]. Similarly, quercetin-loaded nanosystems have been shown to improve intestinal permeability and extend the duration of therapeutic plasma concentrations.

Bone-targeting strategies represent an important frontier in the formulation of plant-based osteogenic agents. Bisphosphonate-conjugated nanoparticles exploit the natural hydroxyapatite-binding affinity of bisphosphonates to selectively accumulate phytochemical payloads at sites of active bone remodeling, thereby increasing local drug concentrations and minimizing systemic exposure [44]. Peptide-functionalized nanocarriers incorporating bone-homing sequences such as aspartate octapeptide (Asp8) have similarly been employed to direct phytochemical delivery to osteoblastic and osteoclastic cells within the bone microenvironment. Cyclodextrin complexation, phospholipid-based self-emulsifying systems, and piperine co-administration as an absorption enhancer have also been utilized to improve the bioavailability of specific plant-derived compounds, most notably curcumin [45]. Hydrogel and scaffold-based delivery systems incorporating phytochemicals show particular promise for local application in fracture healing and bone regeneration contexts. Collectively, these formulation innovations hold the potential to bridge the gap between the substantial *in vitro* potency of plant-derived compounds and the more modest effects observed *in vivo*.

Table 3: Advantages, Limitations, and Pharmacokinetic Considerations of Plant-Derived Compounds for Osteoporosis

Compound	Advantages	Limitations	Pharmacokinetic Considerations
Genistein	Dual ER activity; strong clinical evidence; dietary availability	Hormone-sensitive tissue concerns; variable microbiome metabolism	Moderate oral bioavailability (~20-40%); hepatic conjugation; equol conversion variable
Resveratrol	Sirtuin activation; antioxidant; anti-inflammatory	Rapid metabolism; short half-life; limited large RCT data	Very low native bioavailability; extensive sulfation/glucuronidation; Tmax ~1 hour
Curcumin	Potent anti-inflammatory; wide mechanistic range; low cost	Very poor bioavailability (<1%); unstable at physiological pH	Rapid first-pass metabolism; nanoformulations improve but add cost
Quercetin	Antioxidant; widespread in diet; Nrf2 activation	Moderate bioavailability; protein binding; metabolite variability	Absorbed as aglycone and glucosides; undergoes methylation and glucuronidation
Formononetin	Phytoestrogenic; well-tolerated clinically	Requires gut bacterial conversion; species variation	Converted to equol/daidzein; moderate bioavailability; half-life ~6-8 hours
Ursolic acid	Osteogenic gene activation; anti-obesity effects	Hydrophobic; poor solubility; limited human data	Very poor aqueous solubility; nanoformulations significantly improve absorption

8. Regulatory, Safety, and Commercialization Challenges

The pathway from ethnopharmacological observation and laboratory discovery to regulatory approval and market availability for plant-derived therapeutic agents is complex, costly, and fraught with unique challenges [46]. In most jurisdictions, plant-derived compounds intended for bone health are marketed as dietary supplements or nutraceuticals rather than pharmaceutical drugs, which subjects them to a lighter regulatory framework with lower evidentiary requirements but also limits the health claims that may be made and precludes prescription in clinical osteoporosis management. The United States Food and Drug Administration (FDA) governs botanical products under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which does not require pre-market efficacy demonstration, while the European Medicines Agency (EMA) has established guidelines for botanical medicinal products that require some traditional use documentation and safety data.

Standardization of botanical extracts is a fundamental challenge, given that the chemical composition of plant-derived materials varies substantially with cultivar, growing conditions, harvest timing, post-harvest processing, and extraction methodology [47]. Without standardization to defined marker compounds and validated analytical methods, clinical reproducibility is unattainable and comparative evaluation between studies is compromised. The potential for herb-drug interactions represents an important safety

consideration, particularly for patients with osteoporosis who may be concurrently receiving bisphosphonates, hormone therapy, or other medications. Phytoestrogens, for example, may interact with tamoxifen and other selective estrogen receptor modulators, while compounds such as curcumin can inhibit cytochrome P450 enzymes and P-glycoprotein, altering the metabolism and bioavailability of co-administered drugs [48]. Long-term safety data from adequately powered clinical trials are lacking for most plant-derived compounds, representing a significant impediment to their regulatory approval as therapeutic agents for osteoporosis.

From a commercialization perspective, the absence of intellectual property protection for naturally occurring molecules discourages pharmaceutical industry investment in the costly clinical development programs required to support drug approval. Novel delivery systems and proprietary extract formulations with defined composition offer potential avenues for intellectual property protection and commercial differentiation. Collaborative funding models involving academic institutions, national research agencies, and nutraceutical industry partners may help to bridge the investment gap and advance promising compounds through the translational pipeline. Alignment between regulatory standards for efficacy and safety evaluation across major markets would similarly facilitate global commercial development.

Table 4: Current Research Status and Development Stages of Plant-Based Therapies for Bone Disorders

Compound	Class	Current Stage	Regulatory Status	Key Gaps	Next Steps
Genistein	Isoflavone	Phase III / Post-market	Supplement (US, EU); OTC Italy	Long-term fracture data	Fracture endpoint RCTs; biomarker validation
Resveratrol	Stilbene	Phase II / Pilot trials	Supplement	Bioavailability; large RCTs	Enhanced formulation trials; mechanistic biomarkers
Curcumin	Curcuminoid	Phase I-II (nano-formulations)	Supplement; GRAS status	Clinical BMD data; dose optimization	Bioavailability trials; bone-targeted delivery systems
Formononetin	Isoflavone	Phase II	Supplement / botanical extract	Fracture outcomes; interaction studies	Long-duration RCTs; safety in ER+ populations
Quercetin	Flavonol	Preclinical / early Phase I	Supplement	Human bone efficacy data	Dedicated bone trials; ADME studies
Puerarin	Isoflavone glycoside	Phase II (Chinese RCTs)	TCM botanical drug (China)	Western RCT replication; standardization	International multi-center trials
Berberine	Alkaloid	Preclinical / Phase I	Supplement; some prescription use (China)	BMD and fracture data	Phase II bone-specific trials; combination therapy

9. Conclusion and Future Directions

This review has presented a comprehensive analysis of the scientific evidence underpinning the use of plant-derived compounds for bone health and osteoporosis prevention and management. The collective body of preclinical and emerging clinical data establishes that phytochemicals including isoflavones, polyphenols, flavonoids, and terpenoids engage multiple osteogenic and anti-resorptive mechanisms, offering a multifaceted pharmacological approach to a disorder whose pathophysiology is itself multifactorial. The mechanistic diversity of plant-derived compounds, which simultaneously target bone formation, bone resorption, oxidative stress, and hormonal pathways, represents a potential therapeutic advantage over agents with single mechanisms of action, particularly in the context of combination or adjunctive therapy.

Future research priorities must address the key translational barriers identified in this review. Foremost among these is the development and clinical validation of advanced delivery platforms capable of meaningfully improving the oral bioavailability of promising but pharmacokinetically challenging compounds such as curcumin and resveratrol. Adequately powered, long-duration RCTs with fracture as a primary endpoint are essential to definitively establish clinical efficacy, as surrogate endpoints such as BMD and bone turnover markers, while useful, do not constitute a sufficient evidence base for therapeutic recommendations. Standardization of botanical extracts and rigorous characterization of chemical composition in clinical trial materials are prerequisites for reproducibility and regulatory acceptance. Investigation of the gut microbiome's role in mediating the activity of phytoestrogenic compounds, given its determinative influence on equol production, may enable personalized approaches to isoflavone therapy.

Synergistic combinations of plant-derived compounds with one another or with conventional pharmacotherapy represent an underexplored but promising research avenue. The identification of biomarkers that predict individual response to specific phytochemicals, potentially informed by pharmacogenomic and metabolomic profiling, would facilitate patient stratification and precision medicine approaches to plant-based osteoporosis prevention. International harmonization of regulatory frameworks for botanical medicines would accelerate the clinical development pipeline and improve patient access to evidence-based phytochemical therapies. In conclusion, plant-derived compounds represent a scientifically compelling, clinically promising, and practically accessible frontier in the management of osteoporosis and bone health disorders, with the potential to complement or partially displace conventional pharmacotherapy in appropriately selected patient populations, provided that the translational and regulatory challenges outlined herein are systematically addressed through collaborative and rigorously designed research programs.

Figures



Fig 1: Schematic representation of the bone remodeling cycle and sites of intervention by plant-derived compounds.



Fig 2: Classification framework of plant-derived compounds and their roles in bone metabolism.



Fig 3: Translational pathway from discovery of plant-derived compounds to clinical application in osteoporosis treatment.

References

1. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–33.
3. Burge R, Dawson-Hughes B, Solomon DH, *et al*. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–75.
4. Harvey NC, Odén A, Orwoll E, *et al*. Glucocorticoid use and risk of fracture: a prospective analysis. Bone. 2017;102:105–12.
5. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285(33):25103–8.
6. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest. 2000;106(10):1203–4.
7. Odvina CV, Zerwekh JE, Rao DS, *et al*. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.
8. Saag KG, Petersen J, Brandi ML, *et al*. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27.
9. Shen CL, von Bergen V, Chyu MC, *et al*. Fruits and dietary phytochemicals in bone protection. Nutr Res. 2012;32(12):897–910.

10. Trzeciakiewicz A, Habauzit V, Horcajada MN. When nutrition interacts with osteoblast function: molecular aspects of phenolic compounds. Proc Nutr Soc. 2009;68(4):400–8.
11. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423(6937):349–55.
12. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2(4):389–406.
13. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–8.
14. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42.
15. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–92.
16. Udagawa N, Koide M, Nakamura M, *et al.* Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39(1):19–26.
17. Manolagas SC. Estrogen regulation of osteoblast/osteoclast balance. Endocr Rev. 1999;20(3):345–57.
18. Eastell R, O'Neill TW, Hofbauer LC, *et al.* Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.
19. Orhan IE. Evidence-based complementary and alternative medicine for skeletal health. Curr Drug Metab. 2019;20(6):437–47.
20. Xiao J. Dietary flavonoid aglycones and their glycosides: which show better biological significance? Crit Rev Food Sci Nutr. 2017;57(9):1874–905.
21. Messina M, Watanabe S, Setchell KDR. Report on the 8th international symposium on the role of soy in health promotion and chronic disease prevention. J Nutr. 2009;139(4):796S–802S.
22. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2(5):270–8.
23. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol. 1995;49(2):57–68.
24. Yamaguchi M, Weitzmann MN. The bone anabolic quercetin and the bone catabolic resveratrol: compounds playing complex roles. Mol Cell Biochem. 2011;356(1–2):233–5.
25. Fanti P, Monier-Faugere MC, Geng Z, *et al.* The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int. 1998;8(3):274–81.
26. Morselli E, Maiuri MC, Markaki M, *et al.* Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis. 2010;1:e10.
27. Sharan K, Siddiqui JA, Swarnkar G, *et al.* Role of phytochemicals in the prevention of menopausal bone loss. Nutr Rev. 2009;67(7):399–417.
28. Nishida K, Ohashi N, Yoshida T. Quercetin inhibits the differentiation of osteoclasts from mouse bone marrow cells. Biosci Biotechnol Biochem. 2006;70(9):2202–6.
29. Gao YH, Yamaguchi M. Suppressive effect of genistein on rat bone osteoclasts: involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med. 1999;4(6):651–6.
30. Almeida M, Han L, Martin-Millan M, *et al.* Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282(37):27285–97.
31. Li W, Yu S, Liu T, *et al.* Flavonoid metabolism differences contribute to changes in the extracellular matrix (ECM) of osteoblastic MC3T3-E1 cells. Biochim Biophys Acta. 2011;1810(5):537–47.
32. Bharti AC, Takada Y, Aggarwal BB. Curcumin inhibits RANKL-induced NF-κB activation in osteoclast precursors. J Immunol. 2004;172(10):5940–7.
33. Setchell KDR, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone. Am J Clin Nutr. 2003;78(3 Suppl):593S–609S.
34. Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of equol. J Nutr. 2002;132(12):3577–84.
35. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone. 1993;14(4):595–608.
36. Ishimi Y, Miyaura C, Ohmura M, *et al.* Selective effects of genistein on bone loss. Endocrinology. 1999;140(4):1893–900.
37. Aggarwal BB, Harikumar KB. Therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009;41(1):40–59.
38. Powles TJ, Howell A, Evans DG, *et al.* Red clover isoflavones safety study. Menopause Int. 2008;14(1):6–12.
39. Taku K, Melby MK, Takebayashi J, *et al.* Soy isoflavone effects on bone mineral density. Asia Pac J Clin Nutr. 2010;19(1):33–42.
40. Marini H, Minutoli L, Polito F, *et al.* Genistein and bone metabolism in postmenopausal women. Ann Intern Med. 2007;146(12):839–47.
41. Wong RH, Berry NM, Coates AM, *et al.* Resveratrol improves endothelial function. J Hypertens. 2013;31(9):1895–902.
42. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery. Drug Discov Today. 2003;8(24):1112–20.
43. Shome S, Talukdar AD, Choudhury MD, *et al.* Curcumin nanobiotechnology. J Pharm Pharmacol. 2016;68(12):1481–500.
44. Cole LE, Vargo-Gogola T, Roeder RK. Targeted delivery to bone using bisphosphonates. Adv Drug Deliv Rev. 2016;99(Pt A):12–27.
45. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin. Mol Pharm. 2007;4(6):807–18.
46. Calixto JB. Herbal medicines regulation and quality control. Braz J Med Biol Res. 2000;33(2):179–89.
47. World Health Organization. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva: WHO; 2003.
48. Izzo AA, Ernst E. Herb–drug interactions: systematic review. Drugs. 2009;69(13):1777–98.